Almirall SA - Company Profile
Powered by 
All the data and insights you need on Almirall SA in one report.
$295
- Save hours of research time and resources with
our up-to-date Almirall SA Strategy Report
- Understand Almirall SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Almirall SA (Almirall) is a specialty pharmaceutical company that researches, develops, manufactures, and commercializes proprietary medicines and licensed products. The company’s major area of focus is dermatology covering psoriasis, eczema, psoriasis, oncodermatology, onychomicosis, actinic keratosis, acne and other skin infections. It also develops products for autoimmune diseases including rheumatoid arthritis and multiple sclerosis; and gastrointestinal diseases including irritable bowel syndrome with constipation. The company also works together with small and medium-sized companies and healthcare professionals to develop medical solutions and provide them to patients. It operates through affiliates in Europe and Central America and has R&D centers in Spain and Germany. Almirall is headquartered in Barcelona, Spain.
Headquarters
Spain
Address
Ronda General Mitre, 151, Barcelona, 08022
Website
www.almirall.es
Telephone
34 932 913000
No of Employees
1,904
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALM (MCE)
Revenue (2022)
$967.4M
3.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-998.7%
(2022 vs 2021)
Market Cap*
$2.2B
Net Profit Margin (2022)
XYZ
-960.0%
(2022 vs 2021)
* As of and is in US$
Almirall SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Medicines | Airtal |
| Dermatology Products | Almax |
| Over-the-Counter Products | Actikerall |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In March, the company entered into an agreement with Eloxx Pharmaceuticals to license ZKN-013 for rare dermatological diseases. |
| 2024 | Contracts/Agreements | In February, the company entered into a partnership with the Centre for Genomic Regulation (CRG) to identify biomarkers for novel atopic dermatitis treatments. |
| 2024 | Contracts/Agreements | In January, the company and Microsoft entered into a partnership to advance medical dermatology and foster the development of personalized drugs. |
Competitor Comparison
| Key Parameters | Almirall SA | GSK plc | Laboratorios Farmaceuticos Rovi SA | ALK-Abello AS | Esteve Pharmaceuticals SA |
|---|---|---|---|---|---|
| Headquarters | Spain | United Kingdom | Spain | Denmark | Spain |
| City | Barcelona | Brentford | Madrid | Hoersholm | Barcelona |
| State/Province | - | England | Madrid | - | Barcelona |
| No. of Employees | 1,904 | 70,212 | 2,111 | 2,752 | 1,824 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Carlos Gallardo Pique | Chief Executive Officer; Director; Chairman | Executive Board | 2023 | - |
| Mike McClellan | Chief Financial Officer | Senior Management | 2019 | - |
| Mercedes Diz | Chief Marketing Officer | Senior Management | 2023 | - |
| Isabel Gomes | General Counsel; Chief Legal Officer | Senior Management | - | - |
| Volker Koscielny | Chief Medical Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer